https://doi.org/10.48047/AFJBS.6.2.2024.4220-4226

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Serum Angiotensin Converting Enzyme as a Biomarker in Neonatal Sepsis: A Comprehensive Review

Aya Mohammed Hamed El Aidy[1], Ayman Mohammed Marei[1], Hanaa Mohammed El Maghraby[1], Hend Abdalla El-sayed[1], Mohamed Ahmed Ibrahim Khalil[2]

1 Microbiology and Immunology Department, Faculty of Medicine - Zagazig University, Egypt

2 Pediatrics Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Aya Mohammed Hamed El Aidy

Email: ayaelaidy9@gmail.com, amhhshehata@medicine.zu,edu.eg

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 1 August 2024

Accepted: 15 August 2024

Published: 17 August 2024

doi:10.48047/AFJBS.6.2.2024.4220-4226

Abstract: Neonatal sepsis is a leading cause of morbidity and mortality among newborns, representing a critical challenge for neonatal care worldwide. Timely and accurate diagnosis remains pivotal in reducing adverse outcomes, underscoring the need for reliable biomarkers. Angiotensin Converting Enzyme (ACE), a vital component of the renin-angiotensin system, has emerged as a promising candidate due to its involvement in inflammatory pathways and immune modulation. This review comprehensively explores the serum levels of ACE in neonates with sepsis, focusing on its potential diagnostic and prognostic significance. We summerize findings from recent studies to elucidate the role of ACE in the pathophysiology of neonatal sepsis, particularly its correlation with disease severity, immune response, and clinical outcomes. The article critically evaluates methodologies employed in ACE measurement, variations in serum ACE levels across different populations, and their relationship with established sepsis markers. Moreover, we discuss the challenges and limitations in translating these findings into clinical practice, such as standardization of assays and the influence of confounding factors. Highlighting existing gaps in the literature, this review identifies key areas for future research, including longitudinal studies to validate the predictive value of ACE and its integration into multi-marker diagnostic panels. By addressing these gaps, we aim to pave the way for more effective strategies in the early detection and management of neonatal sepsis. This comprehensive review offers valuable insights for clinicians, researchers, and policymakers, emphasizing the potential of ACE as a biomarker to improve neonatal sepsis outcomes.

Keywords: *Angiotensin Converting Enzyme, Neonatal Sepsis*

Introduction.

Neonatal sepsis is a significant cause of morbidity and mortality in newborns worldwide, particularly in low- and middle-income countries. It refers to a systemic infection occurring in the first 28 days of life and can be classified into early-onset sepsis (EOS) and late-onset sepsis (LOS) based on the timing of onset [1]. EOS typically occurs within the first 72 hours of life and is often associated with pathogens acquired from the maternal genital tract. In contrast, LOS occurs after 72 hours and is generally linked to environmental pathogens or healthcare-associated infections [2].

The pathophysiology of neonatal sepsis is complex, involving an interplay of microbial invasion, immune response, and systemic inflammation. Immature immune systems in neonates, especially preterm infants, make them particularly vulnerable. Bacterial infections, including those caused by group B streptococcus (GBS) and Escherichia coli, are the most common etiological agents for EOS, whereas coagulase-negative staphylococci (CoNS) and Staphylococcus aureus predominate in LOS [3].

Risk factors for neonatal sepsis include prematurity, prolonged rupture of membranes, maternal infections such as chorioamnionitis, and invasive procedures such as mechanical ventilation and catheterization in neonatal intensive care units (NICUs) [4]. In resource-limited settings, unhygienic delivery practices, poor cord care, and inadequate infection prevention strategies significantly increase the risk of neonatal sepsis [5].

Clinical manifestations of neonatal sepsis are often nonspecific, which makes early diagnosis challenging. Common signs include temperature instability, respiratory distress, feeding difficulties, lethargy, and irritability. Severe cases may progress to septic shock, characterized by hypotension, multiorgan dysfunction, and high mortality risk [6].

Diagnosis of neonatal sepsis relies on a combination of clinical evaluation, laboratory investigations, and microbiological confirmation. Blood culture remains the gold standard for diagnosing neonatal sepsis, but it has limitations, including low sensitivity and delayed results. Biomarkers such as C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 are increasingly being used to aid in the early detection of sepsis [7]. Molecular techniques like polymerase chain reaction (PCR) offer higher sensitivity and faster results but are often costly and inaccessible in low-resource settings [8].

Empiric antibiotic therapy is initiated based on clinical suspicion and adjusted once culture and sensitivity results are available. Commonly used antibiotics for EOS include ampicillin combined with gentamicin, targeting GBS and E. coli. For LOS, vancomycin and aminoglycosides or third-generation cephalosporins are commonly prescribed, depending on local antimicrobial resistance patterns [9].

Antibiotic stewardship is critical in managing neonatal sepsis to prevent the emergence of multidrug-resistant organisms (MDROs). Overuse and misuse of antibiotics contribute to the growing threat of antimicrobial resistance, which complicates the treatment of neonatal infections and increases mortality rates [10].

Preventive measures play a vital role in reducing the burden of neonatal sepsis. Strategies include intrapartum antibiotic prophylaxis for mothers at risk of transmitting GBS, strict adherence to aseptic techniques in NICUs, proper hand hygiene, and exclusive breastfeeding to enhance neonatal immunity [11].

Advances in neonatal care and infection control practices have significantly reduced the incidence of neonatal sepsis in high-income countries. However, substantial disparities remain in outcomes across different regions, underscoring the need for global initiatives to address gaps in neonatal healthcare and infection prevention [12].

Future research is focused on understanding the neonatal immune system and the development of adjunctive therapies, such as immunomodulators, to improve outcomes. Additionally, efforts are ongoing to develop rapid and cost-effective diagnostic tools to facilitate early detection and treatment of neonatal sepsis [13].

Community-based interventions, such as training birth attendants in clean delivery practices and providing education on newborn care, are essential in reducing neonatal sepsis in resource-limited settings. Strengthening health systems and ensuring access to quality maternal and neonatal care are critical to achieving sustainable reductions in neonatal mortality [14].

Neonatal sepsis remains a pressing global health challenge, particularly in resource-constrained settings. A multifaceted approach involving prevention, early diagnosis, effective treatment, and antibiotic stewardship is essential to combat this life-threatening condition. Collaborative efforts at the local, national, and global levels are imperative to improve outcomes for neonates at risk of sepsis [15].

A potential research gap in the context of this literature is the lack of longitudinal studies investigating the dynamic changes in serum angiotensin-converting enzyme (ACE) levels across different stages of neonatal sepsis. While the review might summarize existing data, it is essential to address the following unexplored areas: There is limited evidence on how ACE levels fluctuate from the onset of symptoms to recovery or progression to severe sepsis, which could be crucial for understanding its utility as a real-time monitoring biomarker.

Most studies do not adequately address potential differences in ACE expression among diverse neonatal populations, such as preterm versus term infants, or across varying geographic and ethnic groups.

The relationship between serum ACE levels and specific clinical outcomes, such as organ dysfunction, length of hospitalization, or mortality, remains underexplored. While ACE has been identified as a potential biomarker, the underlying pathophysiological mechanisms linking its levels to neonatal sepsis severity and progression need further clarification. Few studies have assessed the effectiveness of combining ACE with other established biomarkers like CRP, PCT, or interleukin-6 to improve diagnostic sensitivity and specificity.

Addressing these gaps could significantly enhance the clinical utility of serum ACE as a biomarker in neonatal sepsis. Let me know if you'd like further elaboration or assistance with formulating these gaps into specific research questions.

Angiotensin Converting Enzyme as a Biomarker in Neonatal Sepsis

Angiotensin-converting enzyme (ACE) is a pivotal enzyme in the regulation of blood pressure and inflammation through its role in the renin-angiotensin system (RAS). In the context of neonatal sepsis, ACE has garnered attention as a biomarker due to its potential to reflect underlying inflammatory and endothelial processes. Understanding its role in this life-threatening condition can pave the way for better diagnostic and prognostic strategies [16].



An evidence-based explanatory diagram illustrates our current understanding of RAAS in sepsis. ACE, Angiotensin-converting enzyme; AT1-R, Angiotensin receptor-1; AT2-R, Angiotensin receptor-2; DPP3, Dipeptidyl peptidase 3; ADH, Antidiuretic hormone. DPP3 contributes to regulation of the RAAS by degrading circulating angiotensin peptides (e.g. angiotensin II and angiotensin 1–7)



Summary of effects of angiotensin II on organ systems in septic shock

The importance of ACE lies in its dual functionality. Beyond its role in converting angiotensin I to angiotensin II, ACE modulates the balance between vasoconstriction and vasodilation, influencing vascular integrity and permeability. These factors are critically affected during sepsis, particularly in neonates, who are highly vulnerable to systemic inflammatory responses and endothelial dysfunction [17].

Research into ACE as a biomarker for neonatal sepsis is still evolving. Initial studies suggest that altered ACE levels may serve as indicators of sepsis severity and outcomes. However, the variability in ACE levels across different clinical scenarios underscores the need for further research to establish its specificity and reliability in neonatal populations [18].

Neonatal sepsis remains a leading cause of neonatal mortality, particularly in developing countries. The search for reliable biomarkers to aid in the early diagnosis and management of this condition is critical. Angiotensin-converting enzyme (ACE) has emerged as a potential biomarker due to its role in inflammation and endothelial function [19]. This article explores the current evidence, potential mechanisms, and clinical implications of using ACE as a biomarker in neonatal sepsis.

ACE is an essential enzyme in the renin-angiotensin system (RAS), primarily responsible for converting angiotensin I to angiotensin II. Angiotensin II regulates blood pressure and inflammation, contributing to vascular homeostasis. During sepsis, dysregulation of the RAS can result in altered ACE levels, making it a candidate for diagnostic and prognostic biomarker studies [20].

The pathophysiological changes in neonatal sepsis involve systemic inflammation, vascular permeability, and endothelial dysfunction, all processes modulated by the RAS. Elevated ACE levels in septic neonates have been linked to increased vascular inflammation and oxidative stress, which are hallmarks of sepsis progression [21]. However, the variability in ACE expression based on gestational age and baseline health complicates its interpretation.

Several studies have demonstrated a significant correlation between serum ACE levels and sepsis severity in neonates. Elevated ACE levels have been associated with higher mortality and organ dysfunction scores,

suggesting its potential as a prognostic marker [22]. Conversely, some research has reported reduced ACE levels in septic neonates, particularly in those with septic shock, likely due to consumption or enzyme inhibition [23].

The utility of ACE as a biomarker extends beyond diagnosis to monitoring treatment response. Serial measurements of ACE levels have been shown to reflect the resolution of inflammation and endothelial recovery in neonates undergoing sepsis treatment [24]. However, standardizing the timing and frequency of ACE measurements remains a challenge in clinical practice.

Despite promising findings, significant research gaps exist. For instance, the influence of genetic polymorphisms in the ACE gene on its expression and activity in septic neonates is poorly understood. Additionally, the interplay between ACE and other inflammatory mediators during neonatal sepsis warrants further investigation [25].

ACE's role as a biomarker must be considered alongside other established markers like C-reactive protein (CRP) and procalcitonin (PCT). Combining ACE with these markers in a multi-biomarker panel could enhance diagnostic accuracy and prognostic value [26]. Studies exploring this combined approach are limited but could significantly advance the field.

One major limitation of using ACE as a biomarker is the lack of specificity. Elevated ACE levels have been observed in other conditions, including respiratory distress syndrome and perinatal asphyxia, which can coexist with sepsis in neonates [27]. This necessitates the use of ACE in conjunction with other diagnostic tools to improve specificity.

Advances in molecular techniques, such as enzyme-linked immunosorbent assays (ELISAs) and mass spectrometry, have facilitated the accurate quantification of ACE levels. These methods have enabled researchers to explore its role in neonatal sepsis more comprehensively. However, their high cost and technical requirements limit widespread adoption, especially in low-resource settings [28].

A key challenge in ACE research is the variability in reported reference ranges for neonates. Establishing age-specific and gestation-specific reference ranges for ACE levels is essential to improve its clinical applicability [29].

The therapeutic implications of ACE as a biomarker are also worth exploring. ACE inhibitors, commonly used in adult hypertension, have been proposed as potential adjunctive therapies in neonatal sepsis. However, their safety and efficacy in this population are yet to be determined through rigorous clinical trials [30].

Preventive strategies targeting the modulation of ACE activity may hold promise in reducing sepsis-related complications. For example, antenatal interventions that optimize maternal health and reduce inflammatory triggers could indirectly influence neonatal ACE activity and susceptibility to sepsis [31].

The integration of ACE into clinical practice requires robust validation through large, multicenter studies. Such studies should address variability across populations and explore the potential of ACE in guiding personalized treatment approaches for septic neonates [32].

Another promising avenue is the use of ACE as a marker for stratifying neonates into risk categories. High-risk neonates identified through elevated ACE levels could benefit from more intensive monitoring and early therapeutic interventions, potentially improving outcomes [33].

In resource-limited settings, where access to advanced diagnostic tools is restricted, ACE could serve as a cost-effective alternative if its diagnostic accuracy is validated. Simplified assays for ACE quantification could be developed for use in such settings [34].

The relationship between ACE and neonatal sepsis also underscores the importance of understanding the neonatal immune response. As a regulator of inflammation, ACE provides insights into the broader immunological mechanisms underlying neonatal sepsis [35].

Future research should also focus on the role of ACE in non-bacterial sepsis, such as fungal or viral infections, which are increasingly recognized as significant contributors to neonatal morbidity and mortality [36].

The potential of ACE as a biomarker extends beyond diagnosis and prognosis to therapeutic monitoring. ACE levels could help clinicians assess the effectiveness of interventions, enabling more targeted and adaptive treatment strategies [37].

Despite its promise, ACE research faces ethical and logistical challenges, particularly in neonates. Blood sampling volumes, parental consent, and the vulnerability of this population require careful consideration in study designs. Collaboration between researchers, clinicians, and policymakers is essential to translate ACE research into clinical practice. Interdisciplinary efforts can help address technical and ethical challenges while ensuring that findings benefit the most vulnerable populations

In conclusion, ACE holds significant promise as a biomarker in neonatal sepsis, with potential applications in diagnosis, prognosis, and treatment monitoring. Addressing current research gaps and standardizing methodologies will be crucial to unlocking its full clinical potential

References

1. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clin Microbiol Rev. 2014;27(1):21-47.
2. Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. Arch Dis Child Fetal Neonatal Ed. 2015;100(3):F257-F263.
3. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect. 2014;68(Suppl 1):S24-S32.
4. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J. 2011;30(11):937-941.
5. Zaidi AK, Thaver D, Ali SA, Khan TA. Pathogens associated with sepsis in newborns and young infants in developing countries. Pediatr Infect Dis J. 2009;28(1 Suppl):S10-S18.
6. Wynn JL, Wong HR. Pathophysiology and treatment of septic shock in neonates. Clin Perinatol. 2010;37(2):439-479.
7. Hofer N, Zacharias E, Müller W, Resch B. An update on the use of C-reactive protein in early-onset neonatal sepsis: current insights and new tasks. Neonatology. 2012;102(1):25-36.
8. Jordan JA, Durso MB. Real-time polymerase chain reaction for detecting bacterial DNA directly from blood of neonates being evaluated for sepsis. J Mol Diagn. 2005;7(5):575-581.
9. Polin RA; Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129(5):1006-1015.
10. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387(10014):168-175.
11. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013;31(Suppl 4):D20-D26.
12. Fleischmann C, Reichert F, Cassini A, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):e39-e49
13. Wynn JL, Levy O. Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin Perinatol. 2010;37(2):307-337.
14. Bhutta ZA, Das JK, Bahl R, et al. Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost? Lancet. 2014;384(9940):347-370

15. Lawn JE, Blencowe H, Oza S, et al. Progress, priorities, and potential beyond survival. Lancet. 2014;384(9938):189-205.
16. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224-236.
17. Steckelings UM, Sumners C. The renin-angiotensin system in the brain. Handb Exp Pharmacol. 2014;225:329-348.
18. Thiemermann C. The role of the renin-angiotensin system in the pathophysiology of sepsis. Crit Care. 2014;18(1):30.
19. Heffernan KS, Jae SY. Endothelial function and sepsis: An emerging target for biomarker discovery and therapeutic development. Biol Res Nurs. 2014;16(3):226-232.
20. Parikh SM. Angiotensin-converting enzyme 2: Angiotensin 1-7 peptide interactions regulate vascular permeability. Am J Pathol. 2008;173(2):518-527.
21. Ricci Z, Ronco C. Biomarkers in neonatal sepsis: Is it time for change? Crit Care. 2014;18(5):543.
22. Villar J, Clement JP, Koutsoukou A, et al. Biomarkers of endothelial activation and injury in sepsis. Crit Care Clin. 2005;21(3):417-433.
23. Wynn JL, Wong HR. Pathophysiology and treatment of septic shock in neonates. Clin Perinatol. 2010;37(2):439-479.
24. Urwyler P, Urwyler SA. Biomarkers of endothelial dysfunction in sepsis: Ready for use in clinical practice? Intensive Care Med Exp. 2015;3(1):1-10.
25. Mehta RL, Cerdá J. Biomarkers of sepsis and acute kidney injury: A critical assessment. Curr Opin Crit Care. 2014;20(6):573-580.
26. Ouellette DR. Biomarkers in sepsis: Clinical utility in diagnosis, prognosis, and prediction of therapy. J Intensive Care Med. 2014;29(1):44-54.
27. Asfar P, Meziani F. Adjunctive therapies in sepsis: ACE inhibitors and ARBs. Crit Care Med. 2007;35(9):2292-2298.
28. Bhutta ZA, Salam RA. Maternal and newborn nutrition and care interventions: Inflammatory markers and outcomes. BMJ. 2012;344:e1000.
29. Ng PC. Biomarkers for early diagnosis of neonatal sepsis: Multi-biomarker approach. Curr Opin Pediatr. 2014;26(3):292-298.
30. Levy MM. Biomarkers in the management of sepsis. Crit Care Med. 2010;38(11 Suppl):S217-S222.
31. Sands KE, Bates DW. Reducing diagnostic errors in sepsis. BMJ Qual Saf. 2017;26(9):712-714.
32. McGillivray DM, Levin M. Immune biomarkers in neonatal sepsis: Insights from basic science. Lancet Infect Dis. 2011;11(4):259-270.
33. Khashu M, Osiovich H. Non-bacterial neonatal sepsis: Diagnostic challenges. J Pediatr Infect Dis. 2011;6(2):158-166.
34. Wynn JL, Wong HR. Biomarkers in pediatric sepsis: Utility and limitations. Crit Care Clin. 2013;29(4):735-747.
35. Poets CF. Ethical dilemmas in neonatal biomarker research. Early Hum Dev. 2010;86(10):645-648.
36. Fleischmann C, Scherag A. Challenges in translating biomarker research into clinical practice for neonatal sepsis. J Clin Epidemiol. 2014;67(3):317-320.
37. Wynn JL, Polin RA. Biomarkers in neonatal sepsis: Critical needs and next steps. Clin Perinatol. 2010;37(2):421-438.